All relevant data are within the paper and its Supporting Information files.

Introduction {#sec004}
============

The increased availability of antiretroviral therapy (ART) has resulted in major reductions in morbidity and mortality in high HIV burden settings. Through significant global scale-up, access to ART is increasing, with around 10 million people in low- and middle-income settings receiving treatment as of the end of 2013, an estimated 65% of the of the global target of 15 million people set for 2015 \[[@pone.0115019.ref001]\].

CD4^+^ T-lymphocytes, also known as the helper T-cells, are the coordinators of the immune response that protects the body against microbial disease, a variety of autoimmune diseases and some forms of cancer. The destruction of CD4^+^ T-lymphocytes by HIV is the main cause of the progressive weakening of the immune system in HIV infection, and leads ultimately to acquired immune deficiency syndrome (AIDS). The CD4 count is a strong predictor of HIV progression to AIDS and death, and is considered the best laboratory marker for deciding when to initiate ART \[[@pone.0115019.ref002],[@pone.0115019.ref003]\]. The use of clinical staging alone to determine the timing of ART initiation is limited by the unreliable correlation between asymptomatic or mild disease and short-term prognosis and may result in dangerous delays in treatment initiation in those without symptoms but with severe immune suppression \[[@pone.0115019.ref004]\].

Prior to 2013, the World Health Organization (WHO) recommended ART initiation in all HIV-infected individuals whose CD4 count has dropped to ≤350 cells/μl, irrespective of clinical symptoms. The WHO 2013 guidelines have raised the threshold for ART initiation to ≤500 cells/μl, with priority given to those with a CD4 count to ≤350 cells/μl, consistent with emerging data, indicating a clinical and public health benefit of earlier treatment and as part of a global effort to get 15 million HIV patients on ART by end of 2015 \[[@pone.0115019.ref005]\].

A number of technologies are available for CD4 enumeration, with considerable variation in cost, complexity, and operating requirements (Tables [1](#pone.0115019.t001){ref-type="table"}--[5](#pone.0115019.t005){ref-type="table"}). The traditional approach to calculating absolute CD4+ T lymphocyte counts is to use the total leukocyte count (or lymphocyte count) obtained from the hematology analyzer and then use the percentage CD4+ T lymphocytes from the flow cytometric analysis to calculate the absolute values---the so-called "dual platform" (DP) approach. Quite often, however, two separate samples are used in the procedure, one to obtain the total leukocyte count using a hematology analyzer and one to undertake the flow cytometry, each having its own in-built variation. Thus, when the results from each are combined to determine the absolute CD4+ T lymphocyte count, the variation is compounded such that inter-laboratory variation between centers can be as high as 40%. Thus, the need to derive accurate and precise absolute CD4+ T lymphocyte counts has led to the development of instruments that can produce both percentage and absolute values, termed the"single platform" approach (SP).

10.1371/journal.pone.0115019.t001

###### Operating characteristics of flow cytometric methods for CD4+ T-cell enumeration, using conventional flow cytometers.
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  FLOW CYTOMETRY USING CONVENTIONAL FLOW CYTOMETER[^a^](#t001fn001){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                   
  ---------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- --------------- -----------------
  Assay name                                                                               Various                                                                                                                          Trucount tubes                                                                                                                  Flow-Count beads                               Perfect-Count   PLG CD4
  Manufacturer                                                                             Various                                                                                                                          Becton Dickinson                                                                                                                Beckman Coulter                                Cytognos        Beckman Coulter
  Compatible with various reagent systems and flow cytometers                              Compatible with various reagent systems and flow cytometers                                                                                                                                                                                                                                                                     
  Instrumentation                                                                          Flow cytometer plus haematology analyser                                                                                         Flow cytometer                                                                                                                  Gating strategy                                                
  Assay principle                                                                          Absolute count calculated using results from flow cytometry together with the total lymphocyte count from haematology analyser   Absolute CD4 counts determined using ratio of CD4 to a known quantity of fluorescent beads---no need for haematology analyser   Gating strategy using total white cell count                   
  Trucount tubes contain premeasured quantity of lyophilised beads                         Liquid beads need accurate pipetting by operator                                                                                 Two different bead populations allow detection of inadequate mixing                                                                                                                            
  Parameters measured                                                                      Absolute CD4 and CD4%                                                                                                            Absolute CD4 and CD4%                                                                                                           Absolute CD4 and CD4%                                          
                                                                                           Others depend on reagent kits/methods                                                                                                                                                                                                                                                                                           
  Specimen                                                                                 500μl whole blood in EDTA                                                                                                        Up to 100μl whole blood in EDTA                                                                                                 100μl whole blood in EDTA                                      
  Throughput                                                                               Up to 250 samples/day                                                                                                            Up to 250 samples/day                                                                                                           Up to 250 samples/day                                          
  Compatible with independent EQA/PT programmes?                                           Yes                                                                                                                              Yes                                                                                                                             Yes                                            Yes             Yes
  Is there access to compatible full process QC reagent?                                   Yes                                                                                                                              Yes                                                                                                                             Yes                                            Yes             N/A
  Maximum length of time from blood draw to testing                                        24 hours                                                                                                                         24 hours                                                                                                                        5 days                                                         
  Can the test be performed on fixed/ stabilised blood                                     Yes                                                                                                                              Yes                                                                                                                             Yes                                            Yes             Yes
  Complexity/training required                                                             Complex. Significant training required.                                                                                          Complex. Significant training required                                                                                          Moderate training requirement                                  
  Environmental/energy issues                                                              Requires uninterrupted mains electricity                                                                                         Requires uninterrupted mains electricity                                                                                        Requires uninterrupted mains electricity                       
  Robustness to heat/humidity                                                              Climate control recommended                                                                                                      Climate control recommended                                                                                                     Climate control recommended                                    
                                                                                           Reagents require refrigeration                                                                                                   Reagents require refrigeration                                                                                                  Reagents require refrigeration                                 

^a^ Various flow cytometers available from various manufacturers. Examples include Becton Dickinson FACSCalibur, Beckman Coulter Epics XL.

10.1371/journal.pone.0115019.t002

###### Operating characteristics of dedicated single platform CD4+ T-cell enumeration systems.
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  DEDICATED SINGLE PLATFORM CD4 SYSTEMS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  -------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------
  Manufacturer                                             Becton Dickinson                                                                                              Millipore (formerly Guava Technologies and now a division of Merck)                                                                                                                                                                            Partec                                                                                                                                                                                                                                                                                                                                                 Apogee flow systems
  Instrumentation                                          Flow cytometer                                                                                                Flow cytometer                                                                                                                                                                                                                                 Flow cytometer                                                                                                                                                                                                                                                                                                                                         Flow cytometer
  Assay principle                                          Dedicated single platform bead-based flow cytometer, two colour, no-lyse no-wash                              Single platform volumetric flow cytometer. Microcapillary flow cell. Previously used EasyCD4 reagents (EasyCD4 system), since replaced by Auto CD4/CD4%. Company also produces the more complex easyCyte instruments, for research use only.   Volumetric SP flow cytometer. Up to 3 parameters (2 colour plus SSC). Simplest is single parameter CD4. For CD4%, 2 colour (CD45/4) + SSC. SL_3 (also called SL green) operates on the same principles but is adaptable to wider applications. Other CyFlow instruments such as SL blue have a wider range of parameters and potential applications.   Volumetric flow cytometer
  Parameters measured                                      Absolute CD4 count and CD4%                                                                                   Absolute CD4 count and CD4%                                                                                                                                                                                                                    Absolute CD4 count and CD4%                                                                                                                                                                                                                                                                                                                            Absolute CD4 and CD4%
  Specimen                                                 50μl whole blood in EDTA                                                                                      10μl whole blood in EDTA                                                                                                                                                                                                                       20μl whole blood in EDTA                                                                                                                                                                                                                                                                                                                               50μl whole blood in EDTA
  Throughput                                               ≥30 samples/hour, at CD4 counts≥400                                                                           100--150 samples/day                                                                                                                                                                                                                           250 samples/day, 400 samples/day with loader                                                                                                                                                                                                                                                                                                           20 samples/hour
  Compatible with independent EQA/PT programmes?           Yes                                                                                                           Yes                                                                                                                                                                                                                                            Yes                                                                                                                                                                                                                                                                                                                                                    No data available
  Is there access to compatible full process QC reagent?   Yes                                                                                                           No manufacturer-produced full process control                                                                                                                                                                                                  Manufacturer produces dry stabilised control blood                                                                                                                                                                                                                                                                                                     No manufacturer-produced full process control
  Maximum length of time from blood draw to testing        Stain within 48 hours of draw (24 hours for CD4%) (store at 20--25°C), analyse within 48 hours of staining.   48 hours                                                                                                                                                                                                                                       48 hours                                                                                                                                                                                                                                                                                                                                               Preferably run within 6--8 hours unless stabilised
  Can the test be performed on fixed/ stabilised blood     Yes                                                                                                           Yes                                                                                                                                                                                                                                            Yes                                                                                                                                                                                                                                                                                                                                                    Yes
  Complexity/training required                             One day training                                                                                              One day training                                                                                                                                                                                                                               Moderate training requirement                                                                                                                                                                                                                                                                                                                          One day training
  Environmental/energy issues                              Requires uninterrupted mains electricity                                                                      Requires uninterrupted mains electricity Less biohazardous waste (reduced by 100 fold)                                                                                                                                                         Mains electricity or car battery or solar panels                                                                                                                                                                                                                                                                                                       UPS with battery back up included. Optional inverter allows instrument to be powered by vehicle battery
  Robustness to heat/humidity                              10--35°C, 5--95% non-condensing humidity. Reagents require refrigeration.                                     Instrument: up to 35°C. 10--90% non-condensing relative humidity. Reagents require refrigeration.                                                                                                                                              Solid state laser more stable than water or air cooled gas lasers at high temperatures. Liquid reagents require refrigeration, or dry reagent kits available which can be stored at up to 60°C in dark for up to 12 months                                                                                                                             Option of thermostable reagents with 9 month shelf life at room temperature. Instrument: 5--35°C, \<90% humidity.

PCA = personal cell analysis, SSC = side scatter.

10.1371/journal.pone.0115019.t003

###### Operating characteristics of manual technologies for CD4+ T-cell enumeration.
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  MANUAL METHODS                                                                                                                                                                         
  -------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Manufacturer                                             Beckman Coulter                                                                                                               Invitrogen/Dynal Biotech
  Instrumentation                                          Light microscope, haemocytometer                                                                                              Fluorescent or light microscope, haemocytometer, magnet
  Assay principle                                          Inert latex spheres coated with monoclonal Ab form rosettes on contact with CD4 cells---readily visible by light microscopy   Magnetic polystyrene beads, coated with mouse monoclonal Ab, allow isolation of CD4+ T cells followed by counting using fluorescent (preferable) or light microscope
  Parameters measured                                      Absolute CD4 count                                                                                                            Absolute CD4 count
  Specimen                                                 100μl whole blood in EDTA                                                                                                     125μl whole blood in EDTA or ACD
  Throughput                                               10 samples/day. Operator fatigue a limitation. Suggest stop counting at 500 cells. Batch size limited to 2 samples            10 samples/day. Operator fatigue a limitation. Suggest stop counting at 500 cells. Batch size limited to 6 samples
  Compatible with independent EQA/PT programmes?           No                                                                                                                            No
  Is there access to compatible full process QC reagent?   No                                                                                                                            No
  Maximum length of time from blood draw to testing        72 hours at 20°C                                                                                                              72 hours at 20°C
  Can the test be performed on fixed/ stabilised blood     No                                                                                                                            Compatible with Cyto-Chex (Streck, USA) stabilised refrigerated samples up to 9 days after collection. Not compatible with TransFix (CytoMark, UK).
  Complexity/training required                             1--3 days training                                                                                                            1--3 days training
  Environmental/energy issues                              Requires power for microscope                                                                                                 Requires power for microscope
  Robustness to heat/humidity                              Reagents need refrigeration                                                                                                   Reagents need refrigeration

10.1371/journal.pone.0115019.t004

###### Operating characteristics of other commercially available technologies for CD4+ T-cell enumeration.
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  OTHER COMMERCIALLY AVAILABLE TECHNOLOGIES                                                                                                                                
  -------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Manufacturer                                             Sysmex                                                                                                          i+MED Laboratories Co. Ltd.
  Instrumentation                                          Haematology analyser                                                                                            Haematology analyser, magnet, rotator
  Assay principle                                          CD4 cell isolation using modified Dynal dynabeads, counting using haematology analyser with specific software   Ferrous beads coated with MT4 mAb bind to CD4 T cells, which are then removed using magnet. Whole blood and CD4-deplete blood counted on haematology analyser. CD4 count and % calculated using established formulae
  Parameters measured                                      Absolute CD4 count and CD4%                                                                                     Absolute CD4 and CD4%
  Specimen                                                 125 μl whole blood in EDTA                                                                                      400μl whole blood in EDTA
  Throughput                                               12 samples/hour                                                                                                 No data available
  Compatible with independent EQA/PT programmes?           No EQA evaluation data available                                                                                No EQA evaluation data available
  Is there access to compatible full process QC reagent?   No data available                                                                                               No data available
  Maximum length of time from blood draw to testing        24 hours at 4 or 20°C                                                                                           No data available
  Can the test be performed on fixed/ stabilised blood     No data available                                                                                               No data available
  Complexity/training required                             Moderate complexity                                                                                             Moderate complexity
  Environmental/energy issues                              Requires power for haematology analyser                                                                         Requires power for haematology analyser and rotator
  Robustness to heat/humidity                              No data available                                                                                               No data available

10.1371/journal.pone.0115019.t005

###### Operating characteristics of Point of Care (POC) technologies for CD4+ T-cell enumeration.
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  POINT OF CARE TECHNOLOGIES                                                                                                                                                                                                                  
  -------------------------------------------------------- ------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------- -----------------------------------------------------
  Manufacturer                                             PointCare Technologies                                                                                 Alere (formerly Inverness Medical)                                          Partec
  Instrumentation                                          Point of care instrument                                                                               Point of care instrument                                                    Point of care instrument
  Assay principle                                          CD4 and haematology contained in one unit.                                                             All test reagents sealed within disposable cartridge.                       Compact flow cytometric device. Uses dry reagents
                                                           Gold nanoparticles conjugated to CD4 antibodies (no fluorescence). LED light source.                   Portable analyser uses static image analysis and cell counting principles   
  Parameters measured                                      Absolute CD4, CD4%, Hb, differential white cell count                                                  Absolute CD4                                                                Absolute CD4 and CD4%
  Specimen                                                 40μl whole blood in EDTA                                                                               25μl capillary or venous blood                                              20μl whole blood in EDTA
  Throughput                                               50 samples/day                                                                                         3 samples/hour                                                              250 samples/day
  Compatible with independent EQA/PT programmes?           No                                                                                                     Under investigation                                                         Compatible with German EQA programme
  Is there access to compatible full process QC reagent?   No data available                                                                                      No data available                                                           Company produce dry stabilised blood samples for QC
  Maximum length of time from blood draw to testing        8 hours                                                                                                24 hours                                                                    Provisional data suggest 24 hrs
  Can the test be performed on fixed/ stabilised blood     No data available                                                                                      Compatible with Transfix (CytoMark, UK)                                     No data available
  Complexity/training required                             Moderate                                                                                               Minimal                                                                     Moderate
  Environmental/energy issues                              Requires mains or battery power                                                                        Requires mains or battery power                                             Requires mains or battery power
  Robustness to heat/humidity                              Reagents do not require refrigeration. Instrument: 18--34°C, \<80% relative humidity, non-condensing   No refrigeration required (dried reagents)                                  No refrigeration required (dried reagents)

Two SP approaches are in widespread use today: volumetric and bead based. The principle of the volumetric approach is that a known volume of sample is passed through the flow cell (and interrogated by the laser beam) in a known amount of time. The alternative approach is to use bead-based technologies where a known number of beads is added to a known volume of sample thus allowing calculation of the bead to cell ratio and the subsequent calculation of the absolute cell count, in this instance, CD4+ T lymphocytes. An important feature of any absolute counting system is pipetting accuracy and minimum sample manipulation. The introduction of SP technologies has had a beneficial effect and lowered inter-laboratory variation in CD4 enumeration.

It is critical that country programmes consider whether these tests can give accurate and reproducible results as well as being appropriate for the setting \[[@pone.0115019.ref006]\]. In particular, we focussed on how bias and misclassification probabilities of different CD4 assays may affect eligibility for ART initiation. Misclassification probabilities give clinically useful measures of test performance and should be reported in evaluations of CD4 technologies. An upward misclassification around a treatment threshold means that a patient who should be eligible for treatment would be denied treatment, while a downward misclassification would not lead to ineligibility for treatment. To date, there have been no systematic reviews of the performance of CD4 technologies. Here we provide an evaluation of the performance characteristics of CD4 technologies through a systematic review of published literature.

Methods {#sec005}
=======

We performed a systematic review of studies evaluating the performance of CD4 enumeration technologies. A search of the Cochrane Library and the Centre for Reviews and Dissemination databases, including the Database of Abstracts of Reviews of Effects (DARE), the National Health Service Economic Evaluation Database (NHS EED) and the National Institute for Health Research Health Technology Assessment (NIHR HTA) database found no existing reviews addressing the review objective.

We followed standard guidance in performing the review \[[@pone.0115019.ref007]\]. Objectives and methods of the review were documented in a review protocol, which is included as [S1 Methods](#pone.0115019.s001){ref-type="supplementary-material"}.

Eligibility criteria {#sec006}
--------------------

Eligibility criteria were defined using the PICOS (Population, Interventions, Comparisons, Outcomes, Study Design) format. Studies evaluating the accuracy and/or precision of any CD4 technology commercially available at the time of the review were considered eligible for inclusion. Currently, no "gold" standard technology or internationally recognised reference preparation exists for CD4 enumeration, and a wide range of flow cytometric technologies have been used as comparators \[[@pone.0115019.ref006]\].

For the purposes of this review, we included studies that used as reference technologies any flow cytometric method considered to be acceptable by the WHO HIV diagnostics working group named in the review protocol ([S1 Methods](#pone.0115019.s001){ref-type="supplementary-material"}).

Information Sources {#sec007}
-------------------

Studies were identified by searching two electronic databases---MEDLINE and EMBASE, scanning the reference lists of the Nature supplement *Evaluating diagnostics*: *the CD4 guide*, and by inviting the WHO working group, whose members are authors of the Nature supplement to identify relevant studies for the review \[[@pone.0115019.ref006],[@pone.0115019.ref008]\].

Search Strategy {#sec008}
---------------

We used the following search terms to search the electronic databases: "CD4", "technolog\*", "methodolog\*", "techn\*", "method\*", "test", "evaluation", "validation", "accuracy", "comparison", "efficacy", "performance", "reproducibility", "precision", "flow AND cytometry". Subject headings included: "CD4 antigen", "antigens, CD4", "CD4 lymphocyte count", "CD4-positive T-lymphocytes", "technology", "methodology", "technique", "evaluation", "clinical evaluation", "economic evaluation", "evaluation research", "evaluation and follow up", "instrument validation", "validation process", "validation study", "evaluation studies as topic", "validation studies", and "flow cytometry". Full electronic search strategies and review protocols are detailed in [S1 Methods](#pone.0115019.s001){ref-type="supplementary-material"}.

Study selection {#sec009}
---------------

Articles were exported from the search database to EndNote and screened for relevance ([Fig. 1](#pone.0115019.g001){ref-type="fig"}). Data were extracted by two independent reviewers (SG and KS) and disagreements resolved through consensus.

![PRISMA flow diagram of study selection.\
EQA: external quality assurance, FC: flow cytometry.](pone.0115019.g001){#pone.0115019.g001}

Data extraction {#sec010}
---------------

The following data were extracted: study location, index test, reference test, and population (HIV positive or HIV positive and negative). Data on accuracy and precision included bias or mean difference and limits of agreement, misclassification probabilities (when sensitivity or specificity values were given, misclassification probabilities were calculated), and coefficient of variation. Where possible, HIV positive data alone were extracted. Where this was not possible, combined HIV positive and negative data were extracted. Only data within the clinically relevant range (thresholds of 200, 350, 500 cells/μl) were extracted as per the inclusion criteria.

Studies should report not only percent misclassification around clinically important CD4 cell thresholds (e.g., 200, 350 or 500 cells/μl), but should also report the magnitude of these misclassifications.

The secondary outcome measure addressed precision or reproducibility. Precision is particularly important when following a patient's serial measurements using the same technology. Precision can be measured within-laboratory or between-laboratories and is expressed as percent coefficient of variation (%CV).

Studies meeting inclusion criteria were also assessed for bias and quality on ten points drawn from the STARD guidelines ([Fig. 2](#pone.0115019.g002){ref-type="fig"}) \[[@pone.0115019.ref009]\]. This review has been reported following the PRISMA statement guidance for reporting of systematic reviews \[[@pone.0115019.ref010],[@pone.0115019.ref011]\].

![Methodological quality of included studies.\
EQA: external quality assurance, IQC: internal quality control.](pone.0115019.g002){#pone.0115019.g002}

Results {#sec011}
=======

A summary of different commercially available CD4 technologies, including their assay principles, operational characteristics and compatibility with international external quality assurance programme reagents, is shown in Tables [1](#pone.0115019.t001){ref-type="table"}--[5](#pone.0115019.t005){ref-type="table"}. Conventional flow cytometry based technologies include DP technologies such as the BD FACSCalibur (BD Biosciences, a division of Becton Dickinson, Franklin Lakes, NJ, USA \[BD\]) and the Epics XL (Beckman Coulter, Inc., Pasadena, CA, USA \[BC\]); bead-based SP technologies such as the BD Trucount Tube, the BC Flow Count Tubes, the Cytognos Perfect Count (Cytognos S.L., Salamanca, Spain \[Cytognos\]), and the BC Pan-leucogating (PLG) FlowCare CD4. Dedicated SP CD4 technologies include bead-based BD FACSCount, and three volumetric assays, Millipore Guava PCA (EMD Millipore, Darmstadt, Germany \[Guava\]), Partec CyFlow Counter (Partec, a division of Sysmex, Corporation, Kobe, Japan \[Partec\]) and Apogee Auto40 Flow Cytometer (Apogee Flow Systems, Hertfordshire, UK \[Apogee\]). There are two manual microscopy based counting methods, the BC Cytospheres and the Dynal T4 Quant (Dynal Biotech ASA, a division of Thermo Fisher Scientific Inc., Waltham, MA, USA \[Dynal\]). Point-of-care (POC) analysers include the Sysmex pocH-100i with Dynabeads from Dynal, the i+MED CD4 Select (i+ MED Laboratories, Bangkok, Thailand \[i+ MED\]), the Pima Analyzer (Alere Inc., Waltham, MA, USA \[Alere\]), and PointCare NOW (PointCare Technologies, Marlborough, MA, USA \[PointCare\]).

Study selection {#sec012}
---------------

This systematic review was first performed in July 2009. Of the 433 studies in the search, 345 were excluded as they were not performance evaluations. After further triage, 20 studies that measured bias, misclassification and/or %CV were accepted for inclusion in this review (PRISMA flow diagram, [Fig. 1](#pone.0115019.g001){ref-type="fig"}). A second search was conducted in April 2013 using the same search strategy and review protocol with the goal of capturing more POC CD4 enumeration technologies in the review. An additional 12 studies were included. A summary of data extracted from all eligible studies with data on bias, misclassifications and/or %CV is shown in [S1 Dataset](#pone.0115019.s002){ref-type="supplementary-material"}.

Study characteristics {#sec013}
---------------------

A summary of study characteristics is shown in [Table 6](#pone.0115019.t006){ref-type="table"}.

10.1371/journal.pone.0115019.t006

###### Characteristics of included studies.
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  Study                                                           Location                                         Laboratory or healthcare level at which the study was performed                     Reference standard                                                      Index test (test under evaluation)                                 Population                                                                           No. of samples used in accuracy studies (n)
  --------------------------------------------------------------- ------------------------------------------------ ----------------------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------------------------ -------------------------------------------------------------------------------
  **Balakrishnan 2004** ^**12**^                                  Chennai, India                                   Charitable foundation clinical/research lab                                         BD FACSCount                                                            Coulter Cytospheres                                                HIV pos                                                                              122
  **Carella 1995** ^**13**^                                       USA                                              Teaching hospital / research lab?                                                   DP FC                                                                   Coulter Cytospheres                                                HIV pos and neg                                                                      117
  **Landay 1993** ^**17**^                                        USA and Uganda                                   University research hospitals                                                       DP FC                                                                   Coulter Cytospheres                                                HIV pos and neg                                                                      382
  **Gernow 1995** ^**15**^                                        Denmark and Ivory Coast                          Not clear                                                                           DP FC                                                                   Coulter Cytospheres                                                HIV pos and neg                                                                      123
  **Didier 2001** ^**14**^                                        Paris                                            Teaching hospital lab                                                               SP FC using BD Trucount tubes                                           Coulter Cytospheres                                                HIV pos and neg                                                                      55
                                                                                                                                                                                                       SP FC using BD Trucount tubes                                           Dynal Dynabeads                                                    HIV pos and neg                                                                      46
                                                                                                                                                                                                       SP FC using BD Trucount tubes                                           BD FACSCount                                                       HIV pos and neg                                                                      45
  **Karcher 2006** ^**16**^                                       Uganda                                           Local lab, field conditions                                                         DP FC                                                                   Coulter Cytospheres                                                HIV pos                                                                              131, from 102 donors
                                                                                                                                                                                                       DP FC                                                                   Partec CyFlow Counter CD4/SCC NLNW                                 HIV pos                                                                              128 from 121 donors
  **Lutwama 2008** ^**18**^                                       Uganda                                           University laboratory                                                               BD FACSCount or FACSCalibur                                             Coulter Cytospheres                                                HIV pos                                                                              1444 (≈497 donors)
                                                                                                                                                                                                       BD FACSCount or FACSCalibur                                             Dynal Dynabeads                                                    HIV pos                                                                              1671
  **Diagbouga 2003** ^**19**^                                     Five countries in West Africa                    Local laboratories                                                                  SP FC using BD Trucount tubes                                           Dynal Dynabeads                                                    HIV pos                                                                              657, from 301 donors
  **Imade 2005** ^**21**^                                         Nigeria                                          University hospital laboratory                                                      Partec CyFlow                                                           Dynal Dynabeads                                                    HIV pos and neg                                                                      40
  **Idigbe 2006** ^**20**^                                        Nigeria                                          Research laboratory                                                                 BD FACSCount                                                            Dynal Dynabeads                                                    HIV pos and neg                                                                      97 (46 HIV pos, 51 neg)
  **Balakrishnan 2006** ^**23**^                                  Chennai, India                                   Charitable foundation clinical/research lab                                         BD FACSCount                                                            Guava Easy CD4                                                     HIV pos and neg                                                                      228
  **Kandathil 2005** ^**24**^                                     South India                                      Medical college laboratory and charitable foundation clinical/research laboratory   BD FACSCount                                                            Guava Easy CD4                                                     HIV pos and neg                                                                      72 (51 HIV pos, 21 neg)
  **Spacek 2006** ^**28**^                                        United States                                    University laboratory                                                               DP FC                                                                   Guava Easy CD4                                                     HIV pos                                                                              77
                                                                  Uganda                                           University laboratory                                                               BD FACSCount                                                            Guava Easy CD4                                                     HIV pos                                                                              141
  **Thakar 2006** ^**29**^                                        Pune, India                                      Research institute                                                                  DP FC                                                                   Guava Easy CD4                                                     HIV pos                                                                              79
  **Pattanapanyasat 2007** ^**25**^                               Bangkok, Thailand                                Teaching hospital laboratory and ministry of public health-cdc lab                  SP FC using BD Trucount tubes                                           Guava Easy CD4                                                     HIV pos                                                                              250
                                                                                                                                                                                                       BD FACSCount                                                            Guava Easy CD4                                                     HIV pos                                                                              250
  **Pattanapanyasat 2008** ^**26**^                               Thailand                                         Teaching hospital laboratory                                                        SP FC using BD Trucount tubes                                           Guava Easy CD4                                                     HIV pos                                                                              150
                                                                                                                                                                                                       BD FACSCount                                                            Guava Easy CD4                                                     HIV pos                                                                              150
                                                                                                                                                                                                       SP FC using BD Trucount tubes                                           Partecv CyFlow SL_3                                                HIV pos                                                                              150
                                                                                                                                                                                                       BD FACSCount                                                            Partec CyFlow SL_3                                                 HIV pos                                                                              150
  **Renault 2010** ^**27**^                                       Burkina Faso                                     Community laboratory                                                                BD FACSCount                                                            Guava Easy CD4                                                     HIV pos                                                                              98
  **Zijenah 2006** ^**36**^                                       Zimbabwe                                         University laboratories                                                             BD FACSCount                                                            Partec CyFlow Counter                                              HIV pos                                                                              150
  **Fryland 2006** ^**32**^                                       Malawi                                           District hospital laboratory                                                        BD FACSCount                                                            Partec CyFlow Counter                                              HIV pos and neg                                                                      311 (276 HIV pos, 35 HIV neg)
  **Cassens 2004** ^**30**^                                       Africa and Asia                                  'Hospital laboratories'                                                             Various                                                                 Partec CyFlow SL (SCC + CD4), NLNW                                 HIV pos and neg                                                                      434
  **Pattanapanyasat 2005 'Evaluation of a new.'** ^**52**^        Bangkok, Thailand                                Teaching hospital laboratory                                                        SP FC using BD Trucount tubes                                           Partec CyFlow SL_3 (using single parameter CD4)                    HIV pos                                                                              200
                                                                                                                                                                                                       BD FACSCount                                                            Partec CyFlow SL_3 (using single parameter CD4)                    HIV pos                                                                              200
  **Manasa 2007** ^**34**^                                        Zimbabwe                                         National reference laboratory                                                       DP FC                                                                   Partec CyFlow SL_3 (SCC +CD4 +CD45) (absolute CD4 and %CD4)        HIV pos                                                                              229
  **Dieye 2005** ^**31**^                                         Senegal                                          Laboratory of a University Hospital                                                 SP FC using BD Trucount tubes                                           Partec CyFlow SL Blue CD45/CD3/CD4 + SCCLNW                        HIV pos and neg                                                                      121 (102 HIV pos donors, 28 neg)
                                                                                                                                                                                                       BD FACSCount                                                            Partec CyFlow SL Blue CD45/CD3/CD4 + SCCNLNW                                                                                                            121 (102 HIV pos donors, 28 neg)
  **Lynen 2006** ^**33**^                                         Cambodia                                         Laboratory of an NGO-run hospital                                                   BD FACSCount                                                            Partec CyFlow SL_3 CD4+SSC LNW manual gating                       'Likely to be HIV positive'                                                          115
  **Strauss 1996** ^**42**^                                       Belgium, UK, USA, Spain                          Research laboratories, teaching hospital laboratory and manufacturer                DP FC                                                                   BD FACSCount                                                       HIV pos and neg                                                                      
  **Lopez 1999** ^**39**^                                         Spain and Portugal                               7 centres: 6 hospital laboratories and one University laboratory                    BD FACScan                                                              BD FACSCount                                                       HIV pos and neg                                                                      49 (37 HIV pos, 12 HIV neg)
  **Johnson 1995** ^**38**^                                       USA                                              University laboratory?                                                              DP FC                                                                   BD FACSCount                                                       HIV pos and neg                                                                      47
  **Nicholson 1994** ^**40**^                                     USA                                              Government laboratory                                                               DP FC                                                                   BD FACSCount                                                       Unknown for accuracy studies                                                         50
  **Lyamuya 1996** ^**22**^                                       Tanzania                                         Teaching hospital laboratory?                                                       DP FC                                                                   BD FACSCount                                                       HIV pos and neg                                                                      173
                                                                                                                                                                                                       DP FC                                                                   Dynal Dynabeads                                                    HIV pos and neg                                                                      189
  **Bergeron 2010** ^**37**^                                      Morocco/Canada                                   National reference laboratories                                                     BD FACSCount                                                            BD FACSCount using Rea T Count dry reagents                        HIV pos                                                                              167
                                                                                                                                                                                                       BD FACSCalibur                                                          BD FACSCount using Rea T Count dry reagents                        HIV-pos                                                                              80
  **Sitoe 2011** ^**41**^                                         Mozambique                                       Not stated                                                                          BD FACSCount using venous blood                                         BD FACSCount using capillary blood                                 HIV pos                                                                              101 adults
                                                                                                                                                                                                       BD FACSCalibur using venous blood                                       BD FACSCalibur using capillary blood                               HIV pos                                                                              101 adults
  **Schnizlein-Bick 2000** ^**46**^                               USA                                              5 NIAID certified FC laboratories                                                   DP FC                                                                   SP FC using BD Trucount tubes                                      HIV pos                                                                              60 common samples shipped to 5 sites, plus 14 local donors at each of 5 sites
  **Nicholson 1997** ^**45**^                                     USA                                              University laboratory                                                               DP FC                                                                   SP FC using BD Trucount tubes                                      HIV pos and neg                                                                      81
  **Higgins 2007** ^**43**^                                       USA                                              Research laboratory                                                                 DP FC                                                                   SP FC using BD Trucount tubes                                      HIV pos                                                                              25
  **Jeganathan 2008** ^**44**^                                    Australia                                        Central laboratory                                                                  DP FC                                                                   SP FC using BD Trucount tubes                                      HIV pos                                                                              60 paired samples from 18 patients
  **Reimann 2000** ^**47**^                                       USA                                              5 clinical FC laboratories                                                          DP FC                                                                   SP FC using BC Flow-Count fluorospheres: two colour + flow count   HIV pos                                                                              ≥14 from each of 5 local sites = 71, plus 67 central specimens
                                                                                                                                                                                                       DP FC                                                                   SP FC using BC Flow-Count fluorospheres: tetraONE system           HIV pos                                                                              ≥14 from each of 5 sites = 71, plus 71 central specimens
  **Storie 2004** ^**48**^                                        UK                                               Teaching hospital laboratory?                                                       SP FC using BD Trucount tubes                                           SP FC using Cytognos Perfect-Count beads                           HIV pos                                                                              104
  **Storie 2003** ^**49**^                                        UK                                               Teaching hospital laboratory?                                                       SP FC with BD Trucount tubes                                            SP FC using flow rate calibration                                  HIV pos                                                                              113
                                                                                                                                                                                                       SP FC with BD Trucount tubes                                            DP PLG                                                             HIV pos                                                                              113
  **Denny 2008** ^**50**^                                         USA                                              5 FC laboratories                                                                   Varied by lab---SP or DP FC                                             DP PLG                                                             HIV pos                                                                              99 samples sent to 5 labs, plus 58 local samples
  **Pattanapanyasat 2005 'A multicentre evaluation.'** ^**35**^   Thailand                                         2xteaching hospital labs, 2xregional hospital labs                                  DP FC                                                                   DP PLG                                                             HIV pos                                                                              611
  **Glencross, 2002** ^**51**^                                    Johannesburg, South Africa                       Teaching hospital laboratory                                                        DP FC                                                                   DP PLG                                                             Not stated                                                                           183
                                                                                                                                                                                                       Volumetric SP FC                                                        DP PLG                                                             Not stated                                                                           112
                                                                                                                                                                                                       SP FC using BD Trucount tubes                                           DP PLG                                                             Not stated                                                                           112
  **Sippy-Chatrani 2008** ^**53**^                                Barbados                                         National HIV laboratory                                                             SP FC with BC Flow-Count fluorospheres                                  SP PLG using BC FlowCARE                                           HIV pos                                                                              153
  **Briggs 2009** ^**54**^                                        UK                                               laboratory                                                                          SP FC                                                                   Sysmex PocH-100i with Dynal Dynabeads                              HIV positive for accuracy studies, HIV positive/ leukaemia /lymphoma for precision   115
  **Srithanaviboonchai 2008** ^**55**^                            Thailand                                         Research lab?                                                                       DP FC                                                                   i+MED CD4 select                                                   HIV positive                                                                         100
  **Mtapuri-Zinyowera 2010** ^**57**^                             Zimbabwe                                         VCT clinic                                                                          SP FC using BD Trucount tubes                                           Alere Pima using capillary blood                                   HIV pos                                                                              165
  **Jani 2011** ^**56**^                                          Mozambique                                       Primary healthcare clinics                                                          BD FACSCalibur                                                          Alere PIMA using capillary and venous blood                        HIV pos                                                                              135
  **Sukapirom 2011** ^**58**^                                     Thailand                                         Teaching hospital laboratory                                                        BD FACSCount                                                            Alere PIMA using venous blood                                      HIV pos                                                                              203
  **Manabe 2012**                                                 Uganda                                           Tertiary hospital laboratory                                                        BD FACSCalibur with TruCount beads                                      Alere PIMA using capillary and venous blood                        HIV pos                                                                              380
  **Herbert 2013** ^**61**^                                       UK                                               Hospital laboratory (HIV service)                                                   Coulter FC 500                                                          Alere PIMA using capillary and venous blood                        HIV pos                                                                              283
  **Bergeron 2012** ^**60**^                                      Belgium, Canada, Mozambique, South Africa, USA   National laboratories                                                               BD FACSCalibur, except in South Africa where the BC Epics-XL was used   PointCare NOW                                                      HIV pos and neg                                                                      472
  **Logan 2013** ^**62**^                                         USA                                              Research laboratory                                                                 BD FACSCalibur                                                          mBio Snap Count using capillary and venous blood                   HIV pos                                                                              146
  **Mbopi-Keou 2012** ^**63**^                                    Cameroon                                         National Health Laboratory                                                          BD FACSCalibur                                                          Apogee Auto40 Flow Cytometer                                       HIV pos and neg                                                                      234 (adults and children)
  **Mbopi-Keou 2012** ^**64**^                                    Cameroon                                         HIV reference Laboratory                                                            BD FACSCalibur                                                          Apogee Auto40 Flow Cytometer                                       volunteers                                                                           257 (adults and children)

FC = flow cytometry.

DP = dual platform.

SP = single platform.

SCC = side scatter.

BD = Becton Dickinson.

BC = Beckman Coulter.

LNW = lyse, no-wash.

NLNW = no-lyse, no-wash.

VCT = Voluntary Counselling and Testing.

At least one published performance evaluation study was found for each of the following technologies: BC Cytospheres \[[@pone.0115019.ref012]--[@pone.0115019.ref018]\], Dynal Dynabeads \[[@pone.0115019.ref014],[@pone.0115019.ref018]--[@pone.0115019.ref022]\], Guava PCA \[[@pone.0115019.ref023]--[@pone.0115019.ref029]\], Partec CyFlow instruments \[[@pone.0115019.ref016],[@pone.0115019.ref026],[@pone.0115019.ref030]--[@pone.0115019.ref036]\], BD FACSCount \[[@pone.0115019.ref014],[@pone.0115019.ref037]--[@pone.0115019.ref042]\]; BD Trucount tubes \[[@pone.0115019.ref043]--[@pone.0115019.ref046]\], BC Flow-Count fluorospheres \[[@pone.0115019.ref047]\], Cytognos Perfect-Count microspheres \[[@pone.0115019.ref048]\], SP Flow Cytometry using flow rate calibration \[[@pone.0115019.ref049]--[@pone.0115019.ref052]\]; BC PLG FlowCARE CD4 \[[@pone.0115019.ref053]\], Sysmex PocH-100i with Dynal Dynabeads \[[@pone.0115019.ref054]\], i+MED CD4 Select \[[@pone.0115019.ref055]\], Alere Pima Analyzer \[[@pone.0115019.ref056]--[@pone.0115019.ref058],[@pone.0115019.ref061]\], PointCare NOW \[[@pone.0115019.ref060]\], Apogee Auto40 \[[@pone.0115019.ref059],[@pone.0115019.ref063],[@pone.0115019.ref064]\] and MBio Snap Count (MBio Diagnostics, Inc., Boulder, CO, USA \[MBio\]) \[[@pone.0115019.ref062]\].

No published, peer-reviewed performance evaluations of the commercially available technology Partec miniPOC were found by our literature search, and the MBio assay is not yet commercially available.

Methodological quality of included studies {#sec014}
------------------------------------------

The findings of the quality assessment of included studies are summarised in [Fig. 2](#pone.0115019.g002){ref-type="fig"}. Most studies reported the index test (test under evaluation) and the reference standard in sufficient detail to be reproduced, but few studies reported whether staff at the evaluation sites were proficient at performing the reference standard and/or sufficiently trained on performing the index test. Few studies reported internal quality controls being performed during the evaluation period. Without these quality measures, it would be difficult to differentiate whether the bias or misclassification between the index and reference tests was due to differences in inherent test characteristics or to operator error.

Manufacturer involvement was evident in a number of studies. Seven studies declared one or more authors to be affiliated with the manufacturer of the index test \[[@pone.0115019.ref012],[@pone.0115019.ref017],[@pone.0115019.ref039],[@pone.0115019.ref042],[@pone.0115019.ref046],[@pone.0115019.ref054]\]. Four studies were partially sponsored by the manufacturer \[[@pone.0115019.ref025],[@pone.0115019.ref026],[@pone.0115019.ref045],[@pone.0115019.ref053]\]. One study stated that the manufacturer's site was one of the study sites \[[@pone.0115019.ref042]\], and four studies declared donation of reagents or equipment by the manufacturer \[[@pone.0115019.ref015],[@pone.0115019.ref029],[@pone.0115019.ref038],[@pone.0115019.ref040]\]. A further four studies could be considered to be calibration or test developers' papers \[[@pone.0115019.ref030],[@pone.0115019.ref049],[@pone.0115019.ref051],[@pone.0115019.ref055]\]. In the absence of definitions for a sponsored study versus an independent evaluation, it is not clear to what extent the inclusion of manufacturers as co-authors of papers influenced the study results.

Accuracy {#sec015}
--------

As there is no international standard for CD4 enumeration, a variety of reference standard technologies were used for evaluating the performance of new CD4 technologies, making it difficult to pool data on bias and misclassification across all studies.

Bias {#sec016}
----

Bias (mean difference) data were collated and represented graphically but only from studies that compared the index tests mean difference to the same reference technology ([Table 6](#pone.0115019.t006){ref-type="table"} and [Fig. 3a, b](#pone.0115019.g003){ref-type="fig"}). FACSCount and FACSCalibur were the most common reference technologies.

![A. Bias compared to FASCount as the reference technology. B. Bias compared to FASCalibur as the reference technology.](pone.0115019.g003){#pone.0115019.g003}

Bias was evaluated at CD4 thresholds of 200 cells/μl and 350 cells/μl using the BD FACSCount as a reference method. For the Pima Analyser, at CD4 counts at both \<350 cells/μl and \>350 cells/μl, the studies found that the Pima Analyser consistently underestimated CD4 counts by-16.6 cells/μl (limits of agreement-88.4, +55.3 cells/μl at \<350 cells/μl) and at-70.7 cells/μl (limits of agreement-216.5, +75 cells/μl) \[[@pone.0115019.ref058]\]. However, when the Guava Easy CD4 was compared to the FACSCount, the bias for CD4 counts \<350 cells/μl was +13 cells/μl (limits of agreement-27, +53) and for cell counts \>350 cells/μl, bias was-45.3 cells/μl \[[@pone.0115019.ref023],[@pone.0115019.ref027]\].

The FACSCalibur, in comparison to the FACSCount, overestimated CD4 counts by +13.1 cells/μl at values of \<350 cells/μl \[[@pone.0115019.ref041]\]. However, bias estimation of manual bead based methods showed underestimation of CD4 counts at \<350 cells/μl of-35.2 cells/μl (limits of agreement-164.9,+ 94.6) and -0.4 cells/μl (limits of agreement-126, +125.2) for BC Cytospheres and Dynal Dynabeads respectively \[[@pone.0115019.ref018]\].

When the overall bias for all CD4 technologies was calculated, this ranged from-70.7 to +47 cells/μl for CD4 counts \>350 cells/ μl and -35.2 to +13.1 cells/μl for CD4 counts \<350 cells/μl when compared to the FASCount as a reference method.

We then progressed to study bias data using a threshold of 200 cells/μl compared to FACSCount as a reference method. A total of six publications were identified covering the following technologies, the Apogee Auto 40 \[[@pone.0115019.ref059]\], Guava Easy CD4 \[[@pone.0115019.ref023],[@pone.0115019.ref025]--[@pone.0115019.ref027]\], and Partec CyFlow Counter \[[@pone.0115019.ref026],[@pone.0115019.ref052]\].

The four studies that had reported data at \<200 cells/μl and compared the Guava Easy CD4 to the FACSCount, all had a positive bias that ranged from +10 to +45.5 cells/μl \[[@pone.0115019.ref023],[@pone.0115019.ref025]--[@pone.0115019.ref027]\]. One study had data for CD4 counts \>200 cells/μl and had a bias of +44.9 cells/μl (limits of agreement-112.6 to + 212.3) \[[@pone.0115019.ref025]\]. It is interesting to note that all studies reporting the performance of the Guava Easy CD4 showed that this assay overestimated CD4 counts compared to the FACSCount \[[@pone.0115019.ref023],[@pone.0115019.ref025]--[@pone.0115019.ref027]\].

Two studies compared the Partec CyFlow Counter to the FACSCount. One showed an over-estimation by +0.8 cells/μl (limits of agreement-21.7 to +23.2) while the other showed an underestimation by-5.8 cells/μl (limits of agreement-37.6 to +25.9) \[[@pone.0115019.ref026],[@pone.0115019.ref052]\].

Overall when comparing the technologies to the FACSCount as a reference method, bias ranged from +44.9 to -12.1 for CD4 counts \>200 cells/ μl and +45.5 to -5.8 for CD4 counts \<200 cells/ μl. Bias using FACSCalibur as a reference method showed similar results to that using FACSCount ([Fig. 3a and b](#pone.0115019.g003){ref-type="fig"}).

Misclassification {#sec017}
-----------------

[Fig. 4](#pone.0115019.g004){ref-type="fig"} showed the range of misclassifications at thresholds of 200 and 350 cells/μl of new CD4 assays compared to different reference standards.

![Misclassification (%), using a CD4 thresholds of 350 cells/μl and 200 cells/μl.](pone.0115019.g004){#pone.0115019.g004}

Nine studies provided data on misclassification probabilities using a cut-off of 350 cells/μl \[[@pone.0115019.ref016],[@pone.0115019.ref018],[@pone.0115019.ref027],[@pone.0115019.ref056],[@pone.0115019.ref060]--[@pone.0115019.ref064]\]. Data were available on the following assays: BC Cytospheres \[[@pone.0115019.ref016],[@pone.0115019.ref018]\], Dynal Dynabeads \[[@pone.0115019.ref018]\], Guava Easy CD4 \[[@pone.0115019.ref027]\], Partec CyFlow Counter \[[@pone.0115019.ref016]\], Pima Analyzer \[[@pone.0115019.ref056],[@pone.0115019.ref061]\], PointCare NOW \[[@pone.0115019.ref060]\], MBio Snap Count \[[@pone.0115019.ref062]\], and Auto40 Flow Cytometer \[[@pone.0115019.ref063],[@pone.0115019.ref064]\].

Two studies \[[@pone.0115019.ref063],[@pone.0115019.ref064]\] evaluated the Auto40 Flow Cytometer compared to the FACSCalibur in Cameroon. One study \[[@pone.0115019.ref063]\] reported upward and downward misclassification probabilities of 8% and 2%, respectively, while another \[[@pone.0115019.ref064]\] found the likelihood of under-treatment (upward misclassification) to be 3% and the probability of over-treatment (downward misclassification) to be 2%.

Karcher *et al*. conducted a large trial in field conditions in Uganda comparing BC Cytospheres and the Partec CyFlow Counter to DP flow cytometry \[[@pone.0115019.ref016]\]. HIV positive patients were recruited, the majority of whom had CD4 counts within a range from 0 to1200 (median 332 cells/μl). Of samples with CD4 counts \<350 cells/μl measured by DP flow cytometry, BC Cytospheres misclassified 16% of the patients as having CD4 counts of \>350 cells/μl, thereby denying them of eligibility for treatment. Similarly for those with CD4 counts \> 350 cells/μl measured by DP flow cytometry, BC Cytospheres misclassified 20%, indicating that 20% of patients not qualifying for treatment using the reference test would have done so if BC Cytospheres were used. Karcher *et al*. also compared the Partec CyFlow to the DP flow cytometer and found that of samples with counts \<350 cells/μl, 29% were misclassified as having \>350 cells/μl by the Partec CyFlow Counter, and 7% of samples with CD4 counts \>350 cells/μl were misclassified downward as being \<350 cells/μl \[[@pone.0115019.ref016]\].

Lutwama *et al*. conducted a large study of manual technologies in Uganda; they recruited only HIV positive patients, the majority of whom had CD4 counts within the clinically important range (range in study: 0--900 cells/μl) using the reference standard technology \[[@pone.0115019.ref018]\]. Of samples with counts of \<350 cells/μl using the reference standard technology, BC Cytospheres misclassified only 1% as \>350 cells/μl. However, of those with counts \>350 cells/μl, 68% were misclassified as \<350 cells/μl (indicating that 68% of patients not qualifying for treatment using the reference test would have done so if BC Cytospheres were used). Dynal Dynabeads had upward and downward misclassification probabilities of 6% and 30% respectively.

Renault *et al*. (2010) conducted a comparison study between the Guava Easy CD4 and FACSCount. Across a range of CD4 (0--1100 cells/μl), the upward and downward misclassification was calculated and found to be 6.1% and 9.4%, respectively \[[@pone.0115019.ref027]\].

One study reported on evaluations of the PointCare NOW assay (this instrument has since been re-marketed/rebranded as HumaCount CD4now (Human Diagnsotics Worldwide mbH, Weisbaden, Germany) in five countries (Mozambique, Belgium, Canada, USA and South Africa) \[[@pone.0115019.ref060]\]. Mozambique, Belgium, Canada and USA used the FACSCalibur as a reference standard while South Africa compared the PointCare NOW to the Epics XL. Upward and downward misclassification were reported by country: Mozambique, +51%, -20%; Belgium, +62%, -4%; Canada, +50%, -0%; USA, +0%, -3%; and for South Africa, +64%, -6%. Overall misclassification was also calculated, and it was found that testing with PointCare NOW would have led to 47% of patients with CD4 counts less than 350 cells/μl not eligible to receive treatment (upward misclassification) and 6% of patients with CD4 counts greater than 350 cells/μl eligible to receive treatment (downward misclassification).

Of the two studies evaluating the Pima Analyzer, Herbert *et al*. (2013) used the BC Cytomics FC 500 as a reference standard while Jani *et al*. compared the Pima Analyzer to the BD FACSCalibur \[[@pone.0115019.ref056],[@pone.0115019.ref061]\]. Across the clinically relevant range (60--1200 cells/μl), Herbert *et al*. found the upward and downward misclassification to be 6.1% and 9.4% respectively. MBio Snap Count was evaluated by Logan *et al*. (2013) and compared to the FACSCalibur \[[@pone.0115019.ref062]\]. Of the 94 samples, 2.1% were misclassified upward and 3.2% were misclassified downward at a threshold of 350 cells/μl.

Thirteen studies presented misclassification data using a CD4 cut-off of 200 cells/μl; these are presented in [Fig. 4b](#pone.0115019.g004){ref-type="fig"} \[[@pone.0115019.ref012],[@pone.0115019.ref013],[@pone.0115019.ref015],[@pone.0115019.ref017],[@pone.0115019.ref018],[@pone.0115019.ref020],[@pone.0115019.ref023],[@pone.0115019.ref028],[@pone.0115019.ref036],[@pone.0115019.ref056],[@pone.0115019.ref060],[@pone.0115019.ref061],[@pone.0115019.ref063],[@pone.0115019.ref064]\].

Even through misclassification probabilities can be influenced by the number of patients with CD4 counts close to the threshold in each study, Pointcare NOW showed an overall tendancy towards upward misclassification at both thresholds of 200 and 350 cells/μl. Most other technologies showed misclassification probabilities of \<10%.

Precision {#sec018}
---------

Forty-four percent of studies reported within-laboratory precision of absolute CD4 count measurement, using replicates of fresh whole blood^.^ \[[@pone.0115019.ref015],[@pone.0115019.ref017],[@pone.0115019.ref019],[@pone.0115019.ref021],[@pone.0115019.ref024],[@pone.0115019.ref029],[@pone.0115019.ref032]--[@pone.0115019.ref034],[@pone.0115019.ref038]--[@pone.0115019.ref042],[@pone.0115019.ref045]--[@pone.0115019.ref047],[@pone.0115019.ref050],[@pone.0115019.ref054],[@pone.0115019.ref056],[@pone.0115019.ref058]\] [Fig. 5](#pone.0115019.g005){ref-type="fig"} shows the inter- and intra assay variations expressed as % CV for the Apogee Auto assay and the intra-assay variation for the mBio SnapCount \[[@pone.0115019.ref062],[@pone.0115019.ref063]\].

![Intra- and inter-assay variation (% CV) for the Apogee Auto 40 and for the MBio SnapCount at thresholds \<350 cells/mL and \>350 cells/mL.](pone.0115019.g005){#pone.0115019.g005}

Five studies reported between-laboratory precision using whole blood. Two were studies evaluating BD FACSCount, \[[@pone.0115019.ref039],[@pone.0115019.ref042]\] one evaluated Panleucogating, \[[@pone.0115019.ref050]\] and two were studies evaluating bead-based SP technology (BD Trucount tubes and BC Flow-Count fluorospheres) \[[@pone.0115019.ref046],[@pone.0115019.ref047]\]. Gernow *et al*. studied the reproducibility of BC Cytospheres and found poor precision, with a coefficient of variation of 58% \[[@pone.0115019.ref015]\]. The study by Landay et al., however, found precision levels more in keeping with the other technologies \[[@pone.0115019.ref017]\].

Overall, in studies addressing between-laboratory precision, SP flow cytometry using BD Trucount tubes or BC Flow-Count fluorospheres showed less inter-laboratory variability than the DP comparators. \[[@pone.0115019.ref046],[@pone.0115019.ref047]\] In addition, Denny *et al*. demonstrated improved inter-laboratory precision using DP Panleucogating compared with technologies which included DP or SP conventional flow cytometry \[[@pone.0115019.ref050]\]. External quality assurance data showed that the BD FACSCount, which is most commonly used a reference standard for CD4 assay evaluations, has within-laboratory and between-laboratory precision of 15% or less \[[@pone.0115019.ref038],[@pone.0115019.ref039],[@pone.0115019.ref042],[@pone.0115019.ref046]\].

Discussion {#sec019}
==========

This review highlights the difficulties of answering clinically relevant questions about CD4 test performance from the published literature. A minority of studies reported clinically useful measures of accuracy, and few POC tests were carried out under field conditions.

It can be seen that whatever technology is chosen, there is variability associated with CD4 measurement. It should be noted that there is also significant physiological variability in CD4 count, that may account for as much as, if not more than, technical variability of CD4 measurement \[[@pone.0115019.ref065]--[@pone.0115019.ref067]\]. Performance characteristics vary between technologies and for the same technology depending on the reference technology used as a comparator. These characteristics have important implications both for individual patient management and for HIV treatment programmes. It is essential to consider assay performance as well as operating characteristics when choosing a technology. However, these data are not always available in the literature, and currently, evaluations are not sufficiently robust or comprehensive to give a clear idea of the comparative merit of different technologies.

Misclassification probabilities describe the likelihood that a test will incorrectly categorise a result as higher or lower than a given cut-off value as measured by a reference standard. They are clinically relevant measures of accuracy, as they can be used to assess the likelihood that a patient will be incorrectly classified above or below a defined CD4 threshold used in clinical decision making. Misclassification probabilities for the same assay can vary not only because the test is compared to different reference standards, but also because the probabilities are affected by the number of samples clustered around the thresholds of 200 or 350 cells/ul.

Two types of misclassification can be defined---upward misclassification and downward misclassification. Upward misclassification around a treatment threshold may be the most clinically important, leading to a delay in starting ART in some patients, with potentially harmful consequences. Downward misclassification on the other hand would be expected to lead to ART use earlier than indicated, with potential implications for cost and drug exposure. Given the trend towards earlier initiation in global and national guidelines, a degree of over-treatment is likely to be preferred over significant under-treatment \[[@pone.0115019.ref068]\]. Furthermore, the use of CD4 counts alone to assess ART immunological failure in the absence of viral load monitoring will, because of the biases observed, lead to some patients not receiving the appropriate clinical intervention.

Misclassification data showed that manual technologies \[[@pone.0115019.ref018]\], particularly the method using BC Cytospheres, were associated with substantial downward misclassification. It would therefore be expected that the implementation of these tests would lead to the decision to treat potentially large numbers of additional patients who have CD4 counts above the guideline threshold when using the reference test. Less upward misclassification was seen, suggesting that under-treatment might be less of a problem with these technologies. Upward misclassification by either manual technology is however likely to be an underestimate as the majority of counts in this study were very low (less than 25% of samples had counts \>200 cells/μl); if the tests were to be used in a population with counts closer to the treatment threshold (as might be the case if used primarily in asymptomatic patients), upwards misclassification would be expected to be higher.

Limited misclassification data were available for the Partec CyFlow instruments. Of concern, one study evaluating the Partec CyFlow Counter under field conditions found 29% upward misclassification; that is, 29% of patients potentially eligible for treatment may have been denied treatment if the Partec CyFlow Counter-determined CD4 counts were the only criteria for assessing eligibility \[[@pone.0115019.ref016]\]. No other studies of the Partec CyFlow Counter or other CyFlow instruments reported misclassification probabilities at 350 cells/μl. Therefore, we do not know if this finding was replicated elsewhere. The Guava PCA (using EasyCD4 reagents) and the Pima Analyzer showed acceptable upward and downward misclassification rates.

There is some disparity in precision reported for the BC Cytospheres, and the reason for this disparity is not clear. The CD4 counts of the 19 samples used for replicate analysis in the study conducted by Gernow *et al* were not stated; however, they included 12 HIV negative samples that might be assumed to have high counts \[[@pone.0115019.ref015]\]. Given that several papers found BC Cytospheres to have poorer performance at higher counts, this may be in keeping with poor reproducibility in these replicates. Another study, conducted by Landay *et al*., found better precision on a sample with a CD4 count of 1200 (%CV 3·5%) than on a sample with a CD4 count of 200 (%CV 10·8%) \[[@pone.0115019.ref017]\]. Manual methods, although employing simple technology, are labor intensive and require significant user skill. Inadequate training, lack of supervision, or user fatigue may lead to poor performance of these techniques. Neither study described the training received by technicians performing the manual tests, nor reported blinding. Between-laboratory precision is likely to be superior with SP technologies (using BD Trucount tubes or BC Flow-Count fluorospheres) than with conventional DP technologies. As more point-of-care devices are introduced to lower levels of the health system, where training and supervision can be challenging, the lack of adequate training and supervision may introduce additional sources of error, contributing to decreased assay precision. This should be addressed through the development of a comprehensive training and supervision policy and implementation plan for the introduction of POC devices. In addition to the studies presented in this review, evaluations have been performed by government agencies and other national bodies that have not been published in peer-reviewed journals. An evaluation of BC Cytospheres published by the Medical Devices Agency of the UK included samples from 17 HIV positive subjects, and compared BC Cytospheres against DP flow cytometry \[[@pone.0115019.ref069]\]. Accuracy was reported using assessment of bias; misclassification probabilities were not reported. Imprecision was addressed using 6--7 replicates of 6 samples, and found a CV range of 3·2--17·6% (mean 8·5%). Unpublished evaluations have not been included in this review.

A recent review of external quality assurance (EQA) programmes involving 58,626 CD4 data sets from over 3,000 laboratories over a 12-year period show that SP technologies consistently give lower relative errors and confidence limits than DP technologies at clinically significant absolute CD4 counts \[[@pone.0115019.ref070]\].

Limitations of this review {#sec020}
--------------------------

Limitations include the fact that we only included papers published in the English language, and we may have overlooked data because of this limitation. Limiting the search to the peer-reviewed literature may have overlooked robust evaluations conducted by national reference facilities or similar institutions.

It is important to consider that the reference standard technologies themselves are not perfect. Misclassification assumes that the reference result is accurate, i.e., the closest approximation to the truth. Thus, a result considered as a misclassification may in fact be correct. The reference technology if performed once may give a result of 340cells/ul, but if performed in duplicate using the same specimen may give results of 340 and 360. It may be important for the reference technology to be performed in duplicate and only when a concordant result is obtained around a threshold of 350 can it be used as the reference standard for the new test.

What constitutes an "acceptable" margin of error and misclassification probabilities around a threshold remain undefined and may vary among sites, depending on local factors such as the distribution of CD4 counts among asymptomatic patients, how often patients undergo repeat CD4 testing, and the implications of potential overtreatment (e.g., cost, long term risk of drug toxicity). However, given the move towards earlier treatment and the use of better-tolerated, less toxic drugs, misclassification that results in overtreatment may be more acceptable than would have previously been the case. It is relatively straightforward for national programmes to decide which technology best fits their needs based purely on cost and operating characteristics; it may be harder to decide what performance characteristics are acceptable, and harder still to obtain data on test performance to inform choice.

Given the potential for testing error, laboratory participation in EQA programmes and access to quality control (QC) reagents are essential. EQA information is not mentioned in the publications included in the review. Without this information, the proficiency of the laboratory staff performing the testing may have contributed to the errors and variation in addition to the assays themselves.

Conclusions {#sec021}
===========

A wide range of bias and percent misclassification around treatment thresholds over the clinically relevant range were reported on the CD4 enumeration technologies included in this review. Less than half the studies reporting assay precision or reproducibility of the CD4 values obtained. This is a rapidly evolving field with new tests under development, and with existing instruments and reagents being regularly replaced by updated versions. A systematic review of POC tests compared to laboratory-based technologies showed that POC CD4 testing can increase retention in care prior to treatment initiation and can also reduce time to eligibility assessment resulting in more eligible patients being initiated on life-saving treatment \[[@pone.0115019.ref071]\]. The lack of standardized methodology on test evaluation, including consensus on reference standards, is a barrier to assessing relative assay performance and could hinder the introduction of new POC assays in countries where they are most needed.

Supporting Information {#sec022}
======================

###### Systematic review protocol.

(DOC)

###### 

Click here for additional data file.

###### Summary of data extracted from eligible studies.

(XLS)

###### 

Click here for additional data file.

###### 

(DOC)

###### 

Click here for additional data file.

We thank Liam Whitby for his input into the study selection process and Maurine Murtagh, Ruth McNerney, Rhosyn Tuta and Chris Sanders for technical assistance.

[^1]: **Competing Interests:**S. Crowe is a co-developer of the Burnet POC CD4 test. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. All other authors have no conflicts of interest.

[^2]: Conceived and designed the experiments: RWP SMC SC ALL BC DB TND TJS WSS. Performed the experiments: RWP KAS SG. Analyzed the data: RWP SMC SC ALL BC DB TND TJS WSS. Wrote the paper: RWP KAS SG SMC SC ALL BC DB TND TJS WSS SE MV NF.
